Benzodiazepine receptor binding of nonbenzodiazepines in vivo: Alpidem, zolpidem and zopiclone
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Several classes of nonbenzodiazepine compounds, including imidazopyridines such as alpidem and zolpidem and cyclopyrrolones, e.g., zopiclone, have effects similar to benzodiazepines and may act at the benzodiazepine receptor in brain. We characterized the binding of these compounds to the benzodiazepine site in three brain regions using specific uptake of the high-affinity ligand [3H]Ro15-1788 (flumazenil). For alpidem, benzodiazepine binding was decreased in cortex and hippocampus with increasing drug dose. For zolpidem, receptor binding was reduced in cortex without a dose-response effect and no effect was observed on cerebellar binding. Zopiclone did not alter binding except for a decrease in binding at the lowest dose evaluated and an increase in binding above control at the highest dose. These data corroborate prior studies indicating that the imidazopyridines appear to act at the benzodiazepine receptor, but do not support receptor subtype selectivity of zolpidem. The limited effect of zopiclone except for increased binding at high doses is also consistent with prior studies suggesting that zopiclone acts at a site distinct from the benzodiazepine receptor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immediate-release and sublingual formulations of zolpidem are characterized by rapid absorption and higher initial plasma concentrations, factors that likely enhance the risk of behavioral reinforcement and recreational use.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [39]
In the citing paper
“Previous studies 39 40 have suggested that high-dose zolpidem use may result in a loss of selectivity for specific GABA A receptor subunits, thereby generating pharmacological effects more closely resembling those of short-acting BZDs.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [39]
In the citing paper
“Notably, the sublingual formulation achieves earlier and higher peak plasma levels than the immediate-release oral form, even at lower doses—a pharmacokinetic profile that may contribute to its greater abuse potential.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [39]
Citations
Cites
Olsen, R. W., McCabe, R. T., & Wamsley, J. K. (1990) · PubMed · Cited by 271
Miller, L. G., Greenblatt, D. J., Barnhill, J. G., & Shader, R. I. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20998-3 · Cited by 220
Self-citationMultiplicity of GABAA-benzodiazepine receptors
Sieghart, W. (1989) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(89)90189-2 · Cited by 162
Langer, S. Z., & Arbilla, S. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90202-x · Cited by 146
Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice
Miller, L. G., Thompson, M. L., Greenblatt, D. J., Deutsch, S. I., Shader, R. I., & Paul, S. M. (1987) · Brain Research · doi:10.1016/0006-8993(87)90023-0 · Cited by 115
Self-citationBenavides, J., Peny, B., Dubois, A., Perrault, G., Morel, E., Zivkovic, B., & Scatton, B. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24071-x · Cited by 93
Miller, L. G., Greenblatt, D. J., Paul, S. M., & Shader, R. I. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22587-3 · Cited by 91
Self-citationBenzodiazepine receptor binding with [3H]-Ro 15-1788
Goeders, N. E., & Kuhar, M. J. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90505-3 · Cited by 77
Trifiletti, R. R., & Snyder, S. H. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15030-x · Cited by 77
The behavioral profile of zolpidem, a novel hypnotic drug of imidazopyridine structure
Sanger, D. J., Perrault, G., Morel, E., Joly, D., & Živković, B. (1987) · Physiology & Behavior · doi:10.1016/0031-9384(87)90359-3 · Cited by 66
Research works printed but not linked: 1
- Haefely, 1985, Recent advances in the molecular pharmacology of benzodiazepine receptors, Adv. Drug Res., 14, 165
Cited by
Greenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
Self-citationClinical Pharmacokinetics of Zopiclone
Fernandez, C., Martin, C., Gimenez, F., & Farinotti, R. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529060-00004 · Cited by 232
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations
Von Moltke, L. L., Greenblatt, D. J., Granda, B. W., Duan, S. X., Grassi, J. M., Venkatakrishnan, K., Harmatz, J. S., & Shader, R. I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00953.x · Cited by 132
Self-citationZolpidem, Triazolam, and Temazepam: Behavioral and Subject-Rated Effects in Normal Volunteers
Rush, C. R., & Griffiths, R. R. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00007 · Cited by 97
Zolpidem-Associated Hallucinations and Serotonin Reuptake Inhibition: A Possible Interaction
Elko, C. J., Burgess, J. L., & Robertson, W. O. (1998) · Journal of Toxicology: Clinical Toxicology · doi:10.3109/15563659809028939 · Cited by 80
Metadata
- Authors
- Byrnes, J. J., Greenblatt, D. J., & Miller, L. G.
- Affiliations
- Tufts University (US)
- Corresponding author
- Miller, Lawrence G.
- Venue
- Brain Research Bulletin
- Publisher
- Elsevier BV
- Published
- 1992-12
- Volume
- 29
- Issue
- 6
- Pages
- 905-908
- ISSN
- 0361-9230 (ISSN-L)
- OpenAlex
- W2005020654
- Cited by
- 46
- References
- 14
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2018: 1 · 2017: 2 · 2015: 3 · 2014: 1 · 2012: 2
- FWCI
- 0.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Brain Research Bulletin (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01mh047598-03)
- National Institute of Mental Health (MH-47598)
- National Institute on Drug Abuse (DA05258)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- benzodiazepine receptor, non-benzodiazepine hypnotics, alpidem, zolpidem, zopiclone, imidazopyridines, cyclopyrrolones, flumazenil binding, receptor binding, dose-response relationship, receptor subtype selectivity, hippocampus, cerebral cortex, cerebellum
- MeSH terms
- Zolpidem, Animals, Brain, Cerebellum, Cerebral Cortex, Dose-Response Relationship, Drug, Flumazenil, Hippocampus, Hypnotics and Sedatives, Imidazoles, Male, Mice, Inbred Strains, Piperazines, Pyridines, Receptors, GABA-A, Reference Values, Anti-Anxiety Agents, Mice, Azabicyclo Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzodiazepine receptor binding of nonbenzodiazepines in vivo: Alpidem, zolpidem and zopiclone. https://app.cochat.ai/papers/10.1016/0361-9230(92)90164-s
- The paper
- Byrnes, J. J., Greenblatt, D. J., & Miller, L. G. (1992). Benzodiazepine receptor binding of nonbenzodiazepines in vivo: Alpidem, zolpidem and zopiclone. Brain Research Bulletin. https://doi.org/10.1016/0361-9230(92)90164-s
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.